IL17A and diabetic kidney disease: Together with our previous study, these bioinformatics analysis results demonstrated that both VEGF-B and IL-17A signaling were highly involved in DKD, suggesting the potential therapeutic value of simultaneously inhibiting those two pathways in DKD treatment.